立体定向体部放疗(SBRT)治疗异时性寡转移性前列腺癌:当前前瞻性证据的系统综述与Meta分析
该系统综述与Meta分析检索MEDLINE和EMBASE,纳入10项前瞻性队列研究、共653例异时性寡转移性前列腺癌患者和1111个病灶,评估SBRT的疗效与毒性。Meta分析显示总局部控制率为97%(95%CI 94-100),中位ADT无生存期为24.7个月(95%CI 20.1-29.2),2年BCFS、PFS和ADTFS分别为33%(95%CI 11-55)、39%(95%CI 24-54)和52%(95%CI 41-62);仅观察到1例3级骨毒性。作者认为SBRT似乎能有效控制总体疾病负荷且显著毒性极小,但当前前瞻性文献稀缺,需进一步前瞻性数据指导治疗推荐。
要点
- 异时性寡转移性前列腺癌患者接受SBRT后总局部控制率达97%(95%CI 94-100)。
- 中位ADT无生存期为24.7个月(95%CI 20.1-29.2个月)。
- 仅观察到1例3级骨毒性,显著毒性极小;但当前前瞻性文献稀缺,需进一步前瞻性数据。
诊断标准与关键数值
- Meta分析报告总局部控制率为97%(95%CI 94-100)。
- 中位ADT无生存期为24.7个月(95%CI 20.1-29.2个月)。
- 2年BCFS为33%(95%CI 11-55)。
- 2年PFS为39%(95%CI 24-54)。
- 2年ADTFS为52%(95%CI 41-62)。
临床应用与阅片要点
- 仅基于随机对照试验数据,接受SBRT的患者发生PSA进展的可能性是观察组的一半。
局限性
- 当前前瞻性文献稀缺。
- 需进一步前瞻性数据以指导治疗推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: In contrast to traditional views of incurability, patients with oligometastatic disease present with an opportunity for disease eradication with aggressive treatment. There is mounting evidence in support of the role of stereotactic body radiotherapy (SBRT) in oligometastatic prostate cancer (OMPC).
METHODS: MEDLINE and EMBASE were queried for prospective cohort studies reporting the outcomes of metachronous OMPC treated with SBRT. The primary outcome was overall local control. Secondary outcomes included androgen deprivation therapy-free survival (ADTFS), biochemical recurrence free survival (BCFS), and progression-free survival (PFS). When appropriate, these endpoints were combined in a meta-analysis.
RESULTS: We screened 356 abstracts and identified 10 studies to include in our analysis, with a total of 653 patients and 1,111 lesions. The maximum number of lesions included in any single study ranged from 3 to 5. PET-CT staging occurred in 92.4% of all patients. SBRT dose varied, with BED1.5 ranging from 152 to 408. Only one Grade 3 bone toxicity was observed. Meta-analysis reported an overall local control rate of 97% (95% CI, 94-100). Median ADTFS was 24.7 months (95% CI, 20.1-29.2 months). Two-year BCFS, PFS, and ADTFS were 33% (95% CI, 11-55), 39% (95% CI, 24-54), and 52% (95%CI, 41-62), respectively. Patients treated with SBRT were half as likely to experience PSA progression than those on observation when looking at randomized control trial data alone.
CONCLUSION: SBRT appears to be effective in controlling overall disease burden in metachronous OMPC patients and is associated with minimal significant toxicity. The current prospective literature is scarce, and further prospective data are needed to guide treatment recommendations.
ADVANCES IN KNOWLEDGE: This study provides a comprehensive summary of the prospective evidence reporting the outcomes of SBRT in the management of OMPC patients. We quantify the rates of local control, biochemical-free recurrence, progression-free survival, and ADT-free survival through meta-analysis.
引用
- Yan M, Moideen N, Bratti VF, et al. Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence. Br J Radiol. 2020. PMID: 32822547. doi:10.1259/bjr.20200496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。